^
    Back
    Association details:
    Biomarker:STK11 mutation
    Cancer:Lung Non-Squamous Non-Small Cell Cancer
    Drug:AiRuiKa (camrelizumab) (PD1 inhibitor) +
    AiTan (rivoceranib) (VEGFR-2 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    IASLC-WCLC 2020
    Title:

    P83.01 - Updated Survival and Biomarker Analysis of Camrelizumab and Apatinib in Previously Treated pts of Advanced Non-Squamous NSCLC

    Published date:
    01/12/2021
    Excerpt:
    Patients of non-squamous NSCLC who received apatinib 250 mg orally once daily in combination with camrelizumab 200 mg intravenously on day 1 every 2 weeks...patients with STK11/KEAP1 mutation had a numerically higher ORR (42.9% vs 28.1%, P =0.327), longer PFS (median 9.4 vs 5.3, P = 0. 592) and statistically significantly longer OS (median NR vs NR, P = 0. 047) than those of wild type…Combined camrelizumab and apatinib had promising antitumor activity...especially in these with STK11 or KEAP1 mutation...
    Trial ID:
    NCT03083041
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Clin Cancer Res
    Title:

    Efficacy and biomarker analysis of camrelizumab in combination with apatinib in patients with advanced non-squamous NSCLC previously treated with chemotherapy

    Published date:
    12/15/2020
    Excerpt:
    ...105 chemotherapy-pretreated patients with non-squamous NSCLC were enrolled and received apatinib 250 mg (recommended phase 2 dose) and camrelizumab….Efficacy of combination therapy was evident across all PD-L1 and tumor mutation burden subgroups, and appeared to be improved in patients with STK11/KEAP1 mutation (mutant vs . wild-type, ORR: 42.9% vs 28.1%; 1-year survival rate: 85.1% vs. 53.1%).
    DOI:
    10.1158/1078-0432.CCR-20-3136